Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 8/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 7/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | DDX3X | O00571 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108623 | 0.95 | DDR1 (0.45) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5107442 | 0.95 | KDR (0.42) | KDRBRAFABL1AURKAAURKB | |
| SCHEMBL5108218 | 0.93 | EPHX2 (0.47) | KDRBRAFABL1DDX3XEGFR | |
| SCHEMBL5106806 | 0.92 | KDR (0.52) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5112292 | 0.90 | KDR (0.43) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5114085 | 0.89 | EGFR (0.44) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5119517 | 0.88 | EPHX2 (0.44) | KDRBRAFABL1DDX3XSRC | |
| SCHEMBL5116511 | 0.88 | ABL1 (0.41) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5109035 | 0.87 | SRC (0.46) | KDRBRAFABL1DDR1DDR2 | |
| SCHEMBL5118082 | 0.87 | BRAF (0.42) | KDRBRAFABL1FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609656-B2 | Heteroarylphenylurea derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1724258-A1 | HETEROARYLPHENYLUREA DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119466-A1 | Heteroarylphenylurea Derivative | CHRM1, CBR3, CHRM2 | KDR 2440/4885BRAF 1735/4885ABL1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.